**Core tip:** We retrospectively analyzed patients with advanced biliary tract cancers treated with 5-fluorouracil plus irinotecan at three institutions, MD Anderson, University of Michigan and Mayo Clinic in Jacksonville. We identified 98 patients with a median age of 60 years, most (72%) of whom had intrahepatic cholangiocarcinoma. Fifty and 36 patients were treated in the second and third-line settings, respectively. The median progression-free survival and overall survival were 2.4 (95%CI: 1.7-3.1) and 6.6 (95%CI: 4.7-8.4) mo, respectively.

INTRODUCTION
============

Biliary tract cancers (BTCs) are rare but aggressive malignancies that arise from epithelial cells in the bile ducts or gallbladder. BTCs are anatomically classified as intrahepatic and extrahepatic (perihilar and distal) cholangiocarcinoma (CCA), and gallbladder carcinoma (GBCA)\[[@B1]-[@B3]\].

In the United States alone, more than 12000 people are estimated to be diagnosed with BTC in 2019\[[@B4]\]. Advanced BTCs are considered aggressive cancers with a reported median overall survival (OS) of approximately 12 mo. Over 85000 people lost their lives to BTC between 1999 and 2014\[[@B5]\], and mortality rates continue to rise\[[@B5],[@B6]\]. It is clear that more effective management strategies are needed to reverse these rising rates, particularly for patients with advanced BTCs. Standard of care first-line therapy for these patients involves multi-agent chemotherapy with gemcitabine and cisplatin\[[@B7]-[@B9]\]. In the phase 3 ABC-02 trial published in 2010, gemcitabine and cisplatin was demonstrated to improve median OS to 11.7 mo from 8.1 mo with gemcitabine alone. However, durable response rates are infrequent, and a substantial number of patients progress quickly. Additional strategies and subsequent lines of therapy remain largely investigational with no clear standard at present, although FOLinic acid and Fluorouracil in combination with either OXaliplatin (FOLFOX) or IRInotecan (FOLFIRI) are often used\[[@B10]-[@B12]\].

The efficacy of FOLFIRI as a first or second-line treatment has been previously assessed in small retrospective studies. In a single institution review of 17 patients with advanced BTC treated with FOLFIRI as first-line therapy, the authors noted a median progression free survival (PFS) and OS of 2.6 and 6.5 mo, respectively\[[@B13]\]. In another retrospective analysis of 64 patients with advanced BTC treated with either FOLFIRI or XELIRI as second-line therapy, Brieau et al\[[@B10]\] observed a similar median PFS and OS of 2.6 and 6.2 mo, respectively. Additionally, a smaller retrospective analysis of five BTC patients treated with either FOLFIRI or FOLFOX as second-line therapy reported a median PFS and OS of 4.4 and 6.1 mo, respectively\[[@B14]\].

The primary objective of this retrospective analysis was to identify the efficacy of irinotecan-based regimens in the management of patients with advanced BTC in a larger multi-institutional cohort.

MATERIALS AND METHODS
=====================

Study cohort
------------

The study was individually approved by the institutional review boards at University of Michigan, University of Texas MD Anderson Cancer Center and Mayo Clinic Cancer Center at Jacksonville. The informed consent was waived for this HIPAA compliant retrospective study. The eligibility criteria included patients aged 18 years or older with pathologic confirmation of BTC and advanced unresectable or metastatic disease on imaging. Eligible subjects must have received irinotecan-based systemic chemotherapy. Patients with ICD9 and ICD10 diagnosis codes for BTC were retrospectively identified at each institution with at least one encounter between January 2007 and October 2017. Data were collected on patient demographics, subtype of BTC, response per RECIST v1.1, progression and survival. In addition, genomic analysis data were also collected, when available.

Statistical analysis
--------------------

Descriptive statistics such as mean, standard deviation, median and range, frequency and percentage were used to summarize patient characteristics. The Kaplan-Meier method was applied to estimate survival outcomes (Figure [1](#F1){ref-type="fig"}), *i.e*., OS and PFS, and the log rank test was used for comparison of these outcomes between subgroups of patients. The OS time was calculated as the time period from the date of the treatment start to the date of death or to the date of the last follow-up for patients alive, and patients alive were censored for the analysis of OS. The PFS time was calculated as the time period from the date of start of treatment to the date of progression or death, whichever occurred first; and patients alive and without progression were censored to the date of the last follow-up. SAS software v9.4 (SAS institute Inc., Cary, NC, United States) and Splus software v8.2 (TIBCO Software Inc., Palo Alto, CA, Unites States).

![The Kaplan-Meier method was applied to estimate survival outcomes. A: Progression-free survival; B: Overall survival.](WJGO-12-83-g001){#F1}

RESULTS
=======

A total of 98 consecutive patients who met the eligibility criteria were included in the analysis. The median age was 60 years (range, 22-86 years), and 46 (46.9%) subjects were women. Sixty-one patients were identified at MD Anderson, 26 at University of Michigan, and 11 at Mayo Clinic Cancer Center in Jacksonville. Seventy-four (75%) patients had distant metastases at the time of treatment with FOLFIRI, while 24 (25%) had locally advanced disease. The majority of patients had intrahepatic CCA (*n* = 71), compared with 17 with GBCA and 10 with extrahepatic CCA. The patient baseline characteristics are detailed in Table [1](#T1){ref-type="table"}.

###### 

Patient baseline characteristics

  **Characteristic**                         **Value**
  ------------------------------------------ ------------
  Total, *n*                                 98
  Age in yr, median (range)                  60 (22-86)
  Gender, *n (%)*                            
  Female                                     46 (47)
  Male                                       52 (53)
  Institution, *n (%)*                       
  MD Anderson Cancer Center                  61 (62)
  University of Michigan                     26 (27)
  Mayo Clinic Cancer Center                  11 (11)
  Stage at Treatment with FOLFIRI, *n (%)*   
  Locally advanced                           24 (25)
  Metastatic                                 74 (75)
  Subtype of BTC, *n (%)*                    
  Extrahepatic cholangiocarcinoma            10 (10)
  Intrahepatic cholangiocarcinoma            71 (72)
  Gallbladder carcinoma                      17 (17)
  Line of Therapy, *n (%)*                   
  First                                      8 (8)
  Second                                     50 (51)
  Third                                      36 (37)
  Fourth or greater                          4 (4)
  Irinotecan-based regimen, *n (%)*          
  FOLFIRI                                    77 (79)
  FOLFIRI + bevacizumab                      13 (13)
  FOLRIRI + anti-EGFR                        5 (5)
  FOLFIRINOX                                 2 (2)
  FOLFIRI + nab-paclitaxel                   1 (1)
  ECOG performance status, *n (%)*           
  0                                          11 (11)
  1                                          48 (49)
  2                                          3 (3)
  3                                          2 (2)
  Not documented                             34 (35)

BTC: Biliary tract cancer; ECOG: Eastern Cooperative Group; EGFR: Epidermal growth factor receptor; FOLFIRI: Folinic acid, 5-fluorouracil and irinotecan; FOLFIRINOX: Folinic acid, 5-fluorouracil, irinotecan and oxaliplatin.

The median duration on FOLFIRI, or FOLFIRI-containing regimens, was 2.2 mo (range, 0.5 to 8.4), and the median PFS was 2.4 mo (95% confidence interval (CI): 1.7-3.1) for the entire cohort. The median PFS for patients treated with FOLFIRI as 1^st^, 2^nd^, 3^rd^ or 4^th^ -- N^th^ line therapy was 3.1 (95%CI: 1.4-4.8), 2.4 (95%CI: 1.8-3.7), 2.3 (95%CI: 1.5-3.1) and 1.5 (95%CI: 0.9-2.0) mo, respectively. The median OS for patients treated with FOLFIRI as 1^st^, 2^nd^, 3^rd^ or 4^th^ -- N^th^ line therapy was 12.3 (95%CI: 5.6-23.4), 7.7 (95%CI: 4.9-10.5), 5.0 (95%CI: 3.6-7.3) and 7.5 (95%CI: 5.2-9.8) mo, respectively. The median OS for the cohort was 6.6 mo (95%CI: 4.7-8.4) from start of therapy. The best overall response rate was 9.8% per RECIST v1.1 with a disease control rate of 45.1%.

Thirteen patients received vascular endothelial growth factor targeted therapy with bevacizumab, and five patients received anti-epidermal growth factor receptor therapy with erlotinib (*n =* 4) and panitumumab (*n =* 1) concurrently with FOLFIRI. Patients in both of these groups of patients exhibited a median PFS of 2.7 mo.

There was no statistically significant difference in median PFS for patients with locally advanced disease when compared to those with distant metastases (3.2 *vs* 2.1 mo, *P =* 0.16) at the time of FOLFIRI treatment. There was a trend towards prolonged median OS for patients with locally advanced cancer compared to those with distant metastases (9.3 *vs* 5.6 mo, *P =* 0.08) (Table [2](#T2){ref-type="table"}).

###### 

Subgroup analysis of median progression-free survival

  **Variable**                      **Median PFS (95%CI)**   ***P* value**   **Median OS (95%CI)**   ***P* value**
  --------------------------------- ------------------------ --------------- ----------------------- ---------------
  Gender                                                                                             
  Female                            2.4 (1.6--3.6)           0.65            6.6 (4.5--9.9)          0.65
  Male                              2.3 (1.5--3.4)                           6.9 (4.6--10.3)         
  Subtype of BTC                                                                                     
  Extrahepatic cholangiocarcinoma   3.7 (1.5--18.9)          0.14            8.0 (1.8--22.3)         0.61
  Intrahepatic cholangiocarcinoma   2.3 (1.9-2.8)                            6.5 (4.5--9.7)          
  Gallbladder carcinoma             2.1 (1.8--3.7)                           6.5 (5.2--10.1)         
  Stage at treatment with FOLFIRI                                                                    
  Locally Advanced                  3.2 (2.0--5.2)           0.16            9.3 (5.9--14.7)         0.08
  Metastatic                        2.1 (1.3--3.3)                           5.6 (3.5--8.8)          
  Line of therapy                                                                                    
  First                             3.1 (1.4--4.8)           0.24            12.3 (5.6--23.4)        0.08
  Second                            2.4 (1.8--3.7)                           7.7 (4.9--10.5)         
  Third                             2.3 (1.5--3.1)                           5.0 (3.6--7.3)          
  Fourth or greater                 1.5 (0.9--2.0)                           7.5 (5.2--9.8)          
  ECOG performance status                                                                            
  0 or 1                            2.5 (2.0--3.1)           0.44            7.7 (5.6--11.9)         0.03
  2 or greater                      1.5 (0.8--4.9)                           2.9 (1.7--8.6)          
  Undocumented                      2.1 (1.6--3.4)                           5.3 (3.8--8.2)          
  Genomic analysis                                                                                   
  *KRAS*                                                                                             
  Wildtype                          2.4 (1.1--5.1)           0.12            11.8 (5.5--25.4)        0.06
  Mutant                            3.7 (1.7--8.0)                           7.5 (3.5--16.1)         
  *FGFR*                                                                                             
  Wildtype                          2.5 (1.0--6.0)           0.29            8.0 (3.3--19.4)         0.56
  Fusion                            4.3 (1.8--10.5)                          13.4 (5.5--32.2)        
  *IDH1*                                                                                             
  Wildtype                          2.7 (1.2--6.0)           0.02            10.8 (4.9--23.9)        0.14
  Mutant                            2.1 (0.9--4.6)                           4.1 (2.3--11.1)         

BTC: Biliary tract cancer; ECOG: Eastern Cooperative Group; FOLFIRI: FOLINIC acid, 5-fluorouracil, irinotecan; OS: Overall survival; PFS: Progression-free survival.

Thirty-four (35%) of the patients included in the study had genomic profiling of their BTC completed, including five with extrahepatic CCA, 27 with intrahepatic CCA and two with GBCA. The genomic profiling results are summarized in Table [3](#T3){ref-type="table"}. The most frequent alterations identified included mutations in *TP53* (35.3%), *IDH1* and *IDH2* (29.4%) and *KRAS* (20.6%) genes. *FGFR*2 fusions were identified in four patients with intrahepatic CCA and two patients with extrahepatic CCA, however, the *IDH1* and *IDH2* mutations were restricted to the intrahepatic subtype.

###### 

Genomic profiling by tumor type

  **Total patients profiled, *n =* 34**   **Cholangiocarcinoma**   **Gallbladder carcinoma, *n =* 2 (6%)**   
  --------------------------------------- ------------------------ ----------------------------------------- ---------
                                                                                                             
  *TP53*                                  \-                       10 (37)                                   2 (100)
  *IDH1*                                  \-                       8 (30)                                    \-
  *KRAS*                                  1 (20)                   6 (22)                                    \-
  *FGFR2*                                 2 (40)                   4 (15)                                    \-
  *IDH2*                                  \-                       2 (7)                                     \-
  *PBRM1*                                 \-                       2 (7)                                     \-
  *BAP1*                                  \-                       2 (7)                                     \-
  *NF1*                                   \-                       1 (4)                                     1 (50)
  *ARID1A*                                \-                       1 (4)                                     1 (50)
  *CDKN2A*                                \-                       \-                                        1 (50)
  *MET*                                   \-                       1 (4)                                     \-
  *CCND1*                                 \-                       1 (4)                                     \-
  *PBX1*                                  \-                       1 (4)                                     \-
  *MYC*                                   \-                       1 (4)                                     \-
  *RB1*                                   \-                       1 (4)                                     \-
  *MAP3K1*                                \-                       1 (4)                                     \-
  *S76*                                   \-                       1 (4)                                     \-
  *SPTA1*                                 \-                       1 (4)                                     \-
  *RET*                                   \-                       1 (4)                                     \-
  *ALK*                                   \-                       1 (4)                                     \-
  *ATM*                                   \-                       1 (4)                                     \-
  *CCNE1*                                 \-                       1 (4)                                     \-
  *GNAS*                                  \-                       1 (4)                                     \-
  *SMAD4*                                 \-                       1 (4)                                     \-
  *PIK3CA*                                \-                       1 (4)                                     \-
  *PIK3CB*                                \-                       1 (4)                                     \-
  *PTEN*                                  \-                       1 (4)                                     \-
  *PALB2*                                 \-                       1 (4)                                     \-
  *ARID2*                                 \-                       1 (4)                                     \-
  *BRCA2*                                 \-                       1 (4)                                     \-
  *BRAF*                                  \-                       1 (4)                                     \-
  *MDM2*                                  1 (20)                   \-                                        \-
  *FRS2*                                  1 (20)                   \-                                        \-

DISCUSSION
==========

In this multi-institution retrospective study, FOLFIRI, or FOLFIRI-containing regimens had modest efficacy with a median PFS of 2.4 mo and OS of 6.6 mo in patients with advanced unresectable or metastatic BTC. To our knowledge, this is the largest analysis of outcomes with FOLFIRI in BTCs. Expectedly, patients treated with FOLFIRI earlier in the course of their therapy tended to have longer PFS (*P =* 0.53), likely due to use of other 5-fluorouracil (5-FU) containing regimens prior to FOLFIRI and development of multi-drug resistance. Additionally, patients with locally advanced stage may have longer PFS (3.2 *vs* 2.1 mo; *P =* 0.16) compared to those with distant metastasis.

The majority of the patients included in our analysis had intrahepatic CCA (72%). This subtype of BTC may be associated with better outcomes compared to extrahepatic CCA and GBCA\[[@B15]\], which could potentially bias our results. However, a difference in survival was not seen in our patients based on subtype of BTC, though the sample size of patients with extrahepatic CCA and GBCA was small.

The survival outcomes we describe are comparable to those reported by Brieau et al\[[@B10]\] and Moretto et al\[[@B13]\] utilizing FOLFIRI and similar to published data regarding other chemotherapy regimens, such as FOLFOX in this patient population\[[@B16],[@B17]\]. FOLFOX has been evaluated in multiple prospective studies as second-line therapy with a reported time to progression of 3.1 mo in a 37 patient phase II trial from China\[[@B18]\] and a PFS of 3.9 mo in a 66 patient observational study from Japan\[[@B19]\]. A retrospective analysis of 144 patients with BTCs treated with second-line chemotherapy (70% regimens 5-FU based) at a single institution in Germany found an overall response rate of 9.7% with a disease control rate of 33.6% and median OS of 9.9 mo\[[@B20]\]. An additional retrospective study of 18 patients from an institution in Chile showed a median PFS and OS of 3.2 and 4.6 mo, respectively\[[@B17]\]. There are several other clinical trials accruing patients for second-line therapy, including the phase Ib/II trial evaluating the combination of 5-FU, folinic acid and nanoliposomal irinotecan in conjunction with an anti-PD1 antibody nivolumab (BilT-03)\[[@B21]\].

In the subgroup of 18 patients who were treated concurrently with either anti-EGFR or anti-vascular endothelial growth factor targeted therapy, there did not appear to be a clinical benefit of the additional drug, though this was a small cohort. This is in contrast to a single institution analysis from France of 13 patients with metastatic intrahepatic CCA treated with FOLFIRI with bevacizumab as second-line therapy that reported a best overall response rate of 38.4%, median PFS of 8 mo and OS of 20 mo\[[@B22]\].

We identified no significant correlation between specific somatic mutations and patient outcomes or response to FOLFIRI, though this conclusion is limited by the small number of patients in our study. Recently, the most promising therapeutic advances in BTC have resulted from the identification and targeting of actionable driver somatic mutations. Multiple phase II clinical trials have yielded encouraging results by taking advantage of driver mutations such as *FGFR*, *IDH1*, *IDH2* and *BRAF*\[[@B23]-[@B26]\]. However, most patients with BTCs do not harbor mutations that are currently targetable, limiting the benefits of these recent advances to only a select cohort.

Given the lack of other standard therapies for patients with BTCs who have progressed on first-line therapy, our results indicate that FOLFIRI may indeed have a role in these patients. The results of our study further emphasize the need for more effective treatment options for patients with advanced unresectable or metastatic BTCs after failure of first-line systemic chemotherapy, especially in absence of actionable driver mutations.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Advanced biliary tract cancers (BTC) are aggressive malignancies without an established standard of care after progression on first-line combination chemotherapy with gemcitabine plus cisplatin. Fluoropyrimidine-based therapies, such as 5-fluorouracil plus either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are commonly used in this setting. There is limited data on the efficacy of such regimens in patients with BTCs, particularly in the patients who have progressed on first-line therapy.

Research motivation
-------------------

There is a significant need for evidence-based treatment of patients with advanced BTCs who have previously progressed of first-line systemic chemotherapy. Only small, primarily single-institution analyses have been published about the role of FOLFIRI in this population. We sought to combine the experiences of multiple institutions to provide the largest dataset with this regimen.

Research objectives
-------------------

Our study assessed the efficacy of FOLFIRI in patients with BTC by measuring progression-free survival and overall survival.

Research methods
----------------

We retrospectively identified patients with advanced, unresectable BTC who were treated with FOLFIRI at three institutions: MD Anderson, University of Michigan and Mayo Clinic in Jacksonville. We collected data on survival, response per RECIST v1.1, patient demographics and tumor characteristics.

Research results
----------------

Ninety-eight patients were included in our analysis, most of whom were treated in the second and third-line setting. Median duration on FOLFIRI was 2.2 mo. Median progression-free survival was 2.4 mo (95%CI: 1.7-3.1), and median overall survival was 6.6 mo (95%CI: 4.7-8.4).

Research conclusions
--------------------

The efficacy of FOLFIRI for patients with BTCs appears to be modest with survival outcomes that are similar to historical controls of other retrospectively examined second-line cytotoxic therapy options.

Research perspectives
---------------------

Based on this multi-institutional analysis, FOLFIRI seems to have a limited role in the treatment of patients with BTCs, though there are no prospective studies that have assessed this regimen in this patient population. The recently reported results of the randomized phase III ABC-06 trial demonstrating an increase in OS with modified FOLFOX plus active symptom control compared to active symptom control alone likely makes this a more appealing treatment option for most patients who have progressed on gemcitabine plus cisplatin.
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